{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Subjects&page=22", "query": { "condition": "Normal Subjects", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 2506, "total_pages": 251, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Subjects&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Normal+Subjects&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T11:19:21.940Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06007690", "title": "A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Choroidal Melanoma", "Indeterminate Lesions", "Uveal Melanoma", "Ocular Melanoma" ], "interventions": [ { "name": "Bel-sar", "type": "DRUG" }, { "name": "Suprachoroidal Microinjector", "type": "DEVICE" }, { "name": "Infrared Laser", "type": "DEVICE" }, { "name": "Sham Infrared Laser", "type": "DEVICE" }, { "name": "Sham Microinjector", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Aura Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "2023-12-06", "completion_date": "2028-08-15", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-26T11:19:21.940Z", "location_count": 25, "location_summary": "Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06007690" }, { "nct_id": "NCT04809623", "title": "Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous Lupus Erythematosus" ], "interventions": [ { "name": "Edecesertib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 3, "start_date": "2021-09-01", "completion_date": "2022-10-18", "has_results": true, "last_update_posted_date": "2024-04-05", "last_synced_at": "2026-10-26T11:19:21.940Z", "location_count": 5, "location_summary": "Beverly Hills, California • Clearwater, Florida • Indianapolis, Indiana + 2 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04809623" }, { "nct_id": "NCT01059448", "title": "Safety and Efficacy of AMG 827 in Subjects With RA", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "AMG 827", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 211, "start_date": "2010-06-03", "completion_date": "2011-04-05", "has_results": true, "last_update_posted_date": "2022-02-28", "last_synced_at": "2026-10-26T11:19:21.940Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • La Jolla, California + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Victorville", "state": "California" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01059448" }, { "nct_id": "NCT03552276", "title": "Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "SUNPG18_07 I (Tildrakizumab 200 mg)", "type": "DRUG" }, { "name": "SUNPG18_07 II (Tildrakizumab 100 mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 281, "start_date": "2018-07-11", "completion_date": "2023-09-18", "has_results": true, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-10-26T11:19:21.940Z", "location_count": 13, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Denver, Colorado + 10 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03552276" }, { "nct_id": "NCT07246590", "title": "Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Common Warts", "Common Warts (Verruca Vulgaris)", "Human Papilloma Virus (HPV)", "Warts" ], "interventions": [ { "name": "VP-102", "type": "COMBINATION_PRODUCT" }, { "name": "Vehicle", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Verrica Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 302, "start_date": "2025-12-17", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-26T11:19:21.940Z", "location_count": 17, "location_summary": "Miami, Florida • Saint Augustine, Florida • Meridian, Idaho + 13 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Saint Augustine", "state": "Florida" }, { "city": "Meridian", "state": "Idaho" }, { "city": "Plainfield", "state": "Indiana" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07246590" }, { "nct_id": "NCT02393248", "title": "Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer", "Solid Tumor", "Gastric Cancer", "Urothelial Cancer", "Endometrial Cancer", "Multiple Myeloma", "Myeloproliferative Neoplasms", "Breast Cancer", "Cholangiocarcinoma", "UC", "MPN" ], "interventions": [ { "name": "Pemigatinib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 201, "start_date": "2015-02-27", "completion_date": "2021-12-17", "has_results": true, "last_update_posted_date": "2023-01-06", "last_synced_at": "2026-10-26T11:19:21.940Z", "location_count": 19, "location_summary": "Birmingham, Alabama • West Hollywood, California • New Haven, Connecticut + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "West Hollywood", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Port Saint Lucie", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02393248" }, { "nct_id": "NCT05253755", "title": "Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "DBI-001", "type": "BIOLOGICAL" }, { "name": "Aqueous gel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "DermBiont, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2021-10-06", "completion_date": "2022-09-09", "has_results": true, "last_update_posted_date": "2023-11-08", "last_synced_at": "2026-10-26T11:19:21.940Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Austin, Texas • Mill Creek, Washington", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Austin", "state": "Texas" }, { "city": "Mill Creek", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05253755" }, { "nct_id": "NCT02561585", "title": "LEO 124249 Ointment in the Treatment of Alopecia Areata", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alopecia Areata" ], "interventions": [ { "name": "LEO 124249", "type": "DRUG" }, { "name": "Vehicle", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2016-01", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2025-03-06", "last_synced_at": "2026-10-26T11:19:21.940Z", "location_count": 2, "location_summary": "Evanston, Illinois • New York, New York", "locations": [ { "city": "Evanston", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02561585" }, { "nct_id": "NCT05695950", "title": "A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dermatomyositis" ], "interventions": [ { "name": "GLPG3667", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lakefront Biotherapeutics NV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 40, "start_date": "2023-02-27", "completion_date": "2026-04-20", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-10-26T11:19:21.940Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Upland, California • Kendall, Florida + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Upland", "state": "California" }, { "city": "Kendall", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05695950" }, { "nct_id": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma", "Renal Cell Carcinoma", "Non-Small Cell Lung Cancer", "Castration-resistant Prostate Cancer", "Triple Negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "Hepatocellular Carcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Colorectal Cancer", "Head and Neck Cancer", "Differentiated Thyroid Cancer", "Lower Esophageal Cancer" ], "interventions": [ { "name": "cabozantinib", "type": "DRUG" }, { "name": "atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 914, "start_date": "2017-09-05", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-26T11:19:21.940Z", "location_count": 57, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03170960" } ] }